1700001F09Rik Inhibitors
Chemical inhibitors of 1700001F09Rik encompass a range of compounds that target various signaling pathways, each with a distinct mode of action. LY294002 and Wortmannin are inhibitors that focus on the phosphoinositide 3-kinases (PI3K) pathway. When PI3K is inhibited, there is a corresponding decrease in the phosphorylation and activation of downstream targets, notably AKT. The activity of 1700001F09Rik, as a part of this pathway, can be inhibited due to the suppression of these downstream signals. Similarly, PD98059 and U0126 act on the MAPK/ERK pathway by obstructing the function of mitogen-activated protein kinase kinase (MEK). This blockade prevents the activation of extracellular signal-regulated kinase (ERK), which can lead to the suppression of 1700001F09Rik if it is indeed regulated by or dependent on the MAPK/ERK cascade.
Furthermore, SB203580 and SP600125 target the stress-activated MAPK pathways, with SB203580 selectively inhibiting p38 MAP kinase, and SP600125 obstructing c-Jun N-terminal kinase (JNK). The inhibition of these kinases can lead to the downregulation of downstream components that are essential for the functional activity of 1700001F09Rik. Rapamycin, by inhibiting the mTOR pathway, also plays a significant role in controlling the activity of 1700001F09Rik, especially if the protein is an element of this particular signaling cascade. On another front, PP2, which targets Src family tyrosine kinases, and Dasatinib, a broad-spectrum tyrosine kinase inhibitor, both prevent the phosphorylation of proteins within their respective pathways, which can suppress the activity of 1700001F09Rik if it is a target within these pathways. Lastly, Y-27632, PD173074, and SU5402 each inhibit specific kinases, namely ROCK kinase, the fibroblast growth factor receptor (FGFR) tyrosine kinase, and FGFR signaling pathways, respectively. The inhibition of these kinases can lead to changes in cell shape, motility, and downstream signaling, which in turn can inhibit the activity of 1700001F09Rik if it is associated with these pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits phosphoinositide 3-kinases (PI3K), which are involved in various signaling pathways, including those regulating cell survival and apoptosis. Inhibition of PI3K by LY294002 could lead to decreased phosphorylation and activation of downstream targets, including AKT. Since 1700001F09Rik is known to be part of the PI3K/AKT pathway, its functional activity could be inhibited as a consequence of the blockade of this pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another potent inhibitor of PI3K. By inhibiting PI3K, Wortmannin would prevent the activation of AKT and potentially other downstream molecules that are critical for cell survival signals. This inhibition can result in a functional blockade of the downstream effects that would include the inhibition of the protein 1700001F09Rik due to the disruption of its associated pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is upstream in the MAPK/ERK signaling pathway. By inhibiting MEK, PD98059 prevents the activation of ERK, a downstream effector that could influence various cellular responses. If 1700001F09Rik is regulated by the MAPK/ERK pathway, its activity would be inhibited as a result of the disruption caused by PD98059. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 also inhibits MEK, therefore impeding the activation of ERK in the MAPK/ERK pathway. The inhibition of this pathway can result in the functional inhibition of 1700001F09Rik if the protein's activity is reliant on signal transduction through ERK. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase, which is part of the stress-activated MAPK pathway. By inhibiting p38 MAP kinase, SB203580 can suppress the downstream signaling that might regulate the function of 1700001F09Rik, assuming 1700001F09Rik is a component or modulator within this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which plays a role in the MAPK signaling pathway. Inhibition of JNK by SP600125 could affect the activity of transcription factors and other proteins regulated by this pathway, potentially including 1700001F09Rik if it is a downstream target of JNK signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
As an mTOR inhibitor, Rapamycin can inhibit the mTOR pathway, which is involved in cell growth and proliferation. The inhibition of mTOR could lead to a functional inhibition of 1700001F09Rik if the protein's activity is dependent on the mTOR signaling cascade. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. These kinases are involved in various signaling pathways, and their inhibition by PP2 could lead to a decrease in the phosphorylation and activity of proteins that are regulated by Src kinases, potentially including 1700001F09Rik. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor with activity against BCR-ABL and Src family kinases. By inhibiting these kinases, Dasatinib could suppress the phosphorylation and subsequent activity of proteins within these signaling pathways, which could include the functional inhibition of 1700001F09Rik. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 inhibits ROCK kinase, which is involved in the regulation of the actin cytoskeleton. Inhibition of ROCK could affect cell shape and motility, potentially leading to functional inhibition of 1700001F09Rik if it is involved in pathways regulated by the actin cytoskeleton. | ||||||